CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $9.66M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Holders
20
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.63M | |
| 2 | +$242K | |
| 3 | +$229K | |
| 4 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$137K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$107K |
Top Sellers
| 1 | -$752K | |
| 2 | -$262K | |
| 3 | -$100K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$98.9K |
| 5 |
LPL Financial
San Diego,
California
|
-$17.1K |